Quent Capital’s Evogene EVGN Stock Holding History

Quent Capital’s Portfolio EVGN Stock Details EVGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,200	Closed	-$12.8K	–	1330
2023 Q2	$12.8K	Buy	+1,200	New	+$8.11K	﹤0.01%	883

Other funds holding EVGN

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Quent Capital's EVGN Position: Q3 2023 in Review

Quent Capital sold out of Evogene (EVGN) in Q3 2023, closing a stake of 1,200 shares — an estimated $12.8K sold.

Quent Capital first reported a position in EVGN in Q2 2023 and held it in 1 quarter. The position peaked at $12.8K in Q2 2023. 35 funds tracked by Wall St. Rank hold EVGN as of Q3 2023.

Quent Capital reported no remaining Evogene position as of Q3 2023 after selling out during the quarter.
Quent Capital sold 1,200 Evogene shares in Q3 2023, an estimated $12.8K.
Quent Capital first reported a position in Evogene in Q2 2023 and held it in 1 quarter.
Quent Capital's Evogene position peaked at $12.8K in Q2 2023.
35 funds tracked by Wall St. Rank held Evogene as of Q3 2023.

Based on Quent Capital's 13F filing for Q3 2023, filed 10 Oct 2023.